BACKGROUND
Therapies using Y-anti-CD20 or I-anti-CD20 have demonstrated their efficacy in patients with B-cell non-Hodgkin's lymphoma. Re is a radionuclide useful for radioimmunotherapy.
OBJECTIVE
To develop a procedure for efficient labelling of anti-CD20 with Re from lyophilized formulations to